MODERATOR
	Neil Love, MD Medical Oncologist Editor, Prostate Cancer Update Research To Practice Miami, Florida
FACULTY AFFILIATIONS
	Peter R Carroll, MD, MPH Professor and Chair Department of Urology Ken and Donna Derr-Chevron Distinguished Professor Director of Clinical Services and Strategic Planning Helen Diller Family Comprehensive Cancer Center; Associate Dean, UCSF School of Medicine San Francisco, California		William K Oh, MD Clinical Director Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts
	Anthony V D’Amico, MD, PhD Professor and Chief of Genitourinary Radiation Oncology Brigham and Women’s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr D’Amico had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Carroll — Speaking Honoraria: AstraZeneca Pharmaceuticals LP, Millennium Pharmaceuticals Inc. Dr Oh — Advisory Committee: Genentech BioOncology, GPC Biotech, Sanofi-Aventis, Wyeth; Speakers Bureau: Sanofi-Aventis.

MODERATOR — Dr Love does not receive any direct remuneration from industry. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.